Dynavax Technologies (NASDAQ:DVAX) Sees Large Volume Increase – Should You Buy?

Dynavax Technologies Corporation (NASDAQ:DVAX) saw an uptick in trading volume on Monday . 4,646,685 shares traded hands during mid-day trading, an increase of 122% from the previous session’s volume of 2,096,736 shares.The stock last traded at $15.3750 and had previously closed at $15.38.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on DVAX. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, October 8th. William Blair cut shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a report on Wednesday, December 24th. Finally, Wall Street Zen raised shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $24.33.

Dynavax Technologies Trading Down 0.0%

The business’s 50-day moving average price is $11.10 and its 200-day moving average price is $10.58. The firm has a market capitalization of $1.81 billion, a PE ratio of -41.55 and a beta of 0.88. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.14 by $0.07. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. The firm had revenue of $94.88 million during the quarter, compared to the consensus estimate of $94.00 million. As a group, analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dynavax Technologies

A number of hedge funds and other institutional investors have recently made changes to their positions in DVAX. Russell Investments Group Ltd. raised its stake in Dynavax Technologies by 770.1% during the 1st quarter. Russell Investments Group Ltd. now owns 20,718 shares of the biopharmaceutical company’s stock valued at $269,000 after acquiring an additional 18,337 shares during the last quarter. Cubist Systematic Strategies LLC increased its holdings in shares of Dynavax Technologies by 237.4% in the first quarter. Cubist Systematic Strategies LLC now owns 656,541 shares of the biopharmaceutical company’s stock valued at $8,515,000 after purchasing an additional 461,980 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Dynavax Technologies in the first quarter valued at approximately $2,205,000. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Dynavax Technologies during the first quarter worth approximately $2,477,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Dynavax Technologies by 1.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 86,421 shares of the biopharmaceutical company’s stock worth $1,126,000 after purchasing an additional 1,625 shares during the period. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.